Agenus (AGEN) Non-Current Deffered Revenue (2010 - 2026)
Agenus (AGEN) posted quarterly Non-Current Deffered Revenue of $1.1 million for Q1 2026, little changed year-over-year from $1.1 million in Q1 2025, and little changed quarter-over-quarter from $1.1 million in Q4 2025.
Analysis
Agenus (AGEN) Non-Current Deffered Revenue (2010 - 2026) Analysis & Trends
Agenus' Non-Current Deffered Revenue history runs 17 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue changed 0.0% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (changed 0.0% YoY), while the FY2025 annual figure was $1.1 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $1.1 million, roughly flat from $1.1 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $8.7 million in Q1 2022, with the low at $1.1 million in Q4 2022.
- The 5-year median for Non-Current Deffered Revenue is $1.1 million (2022), against an average of $2.0 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue tumbled 89.79% in 2022, then changed 0.0% in 2023.
- Agenus' Non-Current Deffered Revenue stood at $1.1 million in 2022, then changed by 0.0% to $1.1 million in 2023, then changed by 0.0% to $1.1 million in 2024, then changed by 0.0% to $1.1 million in 2025, then changed by 0.0% to $1.1 million in 2026.
- Business Quant data shows AGEN's Non-Current Deffered Revenue at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Agenus | 341.87 Mn | 341.87 Mn | 34.52 Mn | 1.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.14 Mn |
| Mar 31, 2026 | 1.14 Mn |
| Dec 31, 2025 | 1.14 Mn |
| Sep 30, 2025 | 1.14 Mn |
| Jun 30, 2025 | 1.14 Mn |
| Mar 31, 2025 | 1.14 Mn |
| Dec 31, 2024 | 1.14 Mn |
| Sep 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 1.14 Mn |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | 1.14 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | 1.14 Mn |
| Dec 31, 2022 | 1.14 Mn |
| Sep 30, 2022 | 3.07 Mn |
| Jun 30, 2022 | 6.17 Mn |
| Mar 31, 2022 | 8.69 Mn |
| Dec 31, 2021 | 11.20 Mn |
| Sep 30, 2021 | 5.41 Mn |